ANZCA Bulletin June 2011 - Australian and New Zealand College of ...

ADVERTISEMENT
Postoperative pain relief
that’s fast, and lasts1 *
*DYNASTAT is indicated as a single perioperative dose for the management of postoperative
pain. Before prescribing, please review Product Information.
(parecoxib sodium for injection)
PBS Information: This product is not listed on the PBS.
BEFORE PRESCRIBING, PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE FROM PFIZER AUSTRALIA PTY LTD.
MINIMUM PRODUCT INFORMATION
DYNASTAT Injection (parecoxib) 40 mg Powder and Diluent for Injection. Indications: single peri-operative dose for post-operative pain. Contraindications:
CABG or other major vascular surgery; unstable or significant established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease;
hypersensitivity to ingredients; allergic-type reactions to sulfonamides, aspirin, NSAIDs or COX-2 inhibitors; severe hepatic impairment (Child-Pugh score ≥10).
Precautions: assess patient’s overall risks before prescribing; use lowest effective dose & do not exceed 40 mg; significant and multiple risk factors for CV events
(hypertension, hyperlipidaemia, diabetes, smoking); signs of serious skin reactions (rash, mucosal lesions) or hypersensitivity; may mask fevers; monitor incisions
for infection; history of GI ulcer disease or bleeding; asthma; renal or hepatic impairment or disease; dehydration; †hypertension; fluid retention, †compromised
cardiac function, †pre-existing oedema, †diuretic treatment, †risk of hypovolemia; pregnancy and lactation; children, elderly; concomitant use with ACE inhibitors or
angiotensin receptor antagonists and thiazide diuretics. See full PI for details. Adverse events: nausea, vomiting, hypertension, hypotension, dizziness, dyspepsia,
constipation, hypokalaemia, ecchymosis, agitation, insomnia, postoperative anaemia, respiratory insufficiency, wound infection, gastroduodenal ulceration, bradycardia,
hyperglycaemia, thrombocytopenia, cerebrovascular disorders. Rarely: acute renal failure, aseptic meningitis, CHF, anaphylaxis, angioedema, erythema multiforme,
hepatic failure, hepatomegaly, jaundice, Stevens-Johnson syndrome. Myocardial infarction (very rare), exfoliative dermatitis, toxic epidermal
necrolysis (rarely) have been reported for valdecoxib (parecoxib is converted to valdecoxib in the body). See full PI for details. Dosage and
administration: single 40 mg IV or IM dose. Based on TGA approved Product Information of 6 July 2006 and amended 16 December 2009.
†
Please note changes to Product Information.
Reference: 1. DYNASTAT Approved Product Information. Pfizer Australia Pty Ltd, ABN 50 008 422 348. 38–42 Wharf Road, West Ryde,
NSW 2114, Australia. Pfizer Medical Information: 1800 675 229. www.pfizer.com.au. Trademark. 03/10 H&T PPU0363.